These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16916270)

  • 21. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
    Ellsworth P
    Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment of overactive bladder: an overview.
    Gupta K; Kaushal S
    Curr Clin Pharmacol; 2012 Aug; 7(3):229-39. PubMed ID: 22564120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Actual treatment of overactive bladder and urge urinary incontinence.
    Cornu JN
    Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview.
    Cipullo LM; Cosimato C; Filippelli A; Conti V; Izzo V; Zullo F; Guida M
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():27-34. PubMed ID: 24411952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
    El-Zawahry A
    Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for overactive bladder.
    Karmarkar R; Khullar V
    Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
    Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
    J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.
    Zacche MM; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1365-74. PubMed ID: 24899225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary incontinence in men: current and developing therapy options.
    Burden H; Abrams P
    Expert Opin Pharmacother; 2016; 17(5):715-26. PubMed ID: 26800277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug therapy for overactive bladder.
    Izett M; Zacchè M; Giarenis I; Robinson D; Cardozo L
    Minerva Ginecol; 2015 Dec; 67(6):557-74. PubMed ID: 26365572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etiology and treatment of overactive bladder in women.
    Shaw HA; Burrows LJ
    South Med J; 2011 Jan; 104(1):34-9. PubMed ID: 21079535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Has the cost of anti-muscarinic a key role in the success rate of patients diagnosed with overactive bladder syndrome?
    Vecchioli Scaldazza C; Morosetti C; Pace G; Azizi B; Giannubilo W; Ferrara V
    Arch Ital Urol Androl; 2012 Jun; 84(2):68-73. PubMed ID: 22908774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Developments in the medical treatment of overactive bladder].
    Alcántara Montero A
    Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.